CARM — Carisma Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $10.43m
- -$6.55m
- $19.63m
- 32
- 41
- 22
- 22
Annual cashflow statement for Carisma Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.4 | -0.336 | -19.9 | -86.9 | -60.5 |
| Depreciation | |||||
| Non-Cash Items | -9.42 | -20 | -18.2 | 8.3 | 9.16 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.861 | -48.6 | 63 | -5.44 | -12 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -30.8 | -68.9 | 24.9 | -81.2 | -59.9 |
| Capital Expenditures | -0.008 | -0.004 | — | -1.13 | -0.123 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -54 | 73.5 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.008 | -0.004 | -54 | 72.4 | -0.123 |
| Financing Cash Flow Items | — | -0.001 | — | 31.9 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 38.1 | 176 | 0.001 | 62.2 | 0.344 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.27 | 107 | -29.1 | 53.4 | -59.7 |